I studie WV16240 var primære endepunkter for effekt HBeAg- serokonversion og HBV- DNA under 105 kopier/ ml.
In study WV16240, the primary efficacy endpoints were HBeAg seroconversion and HBV-DNA below 105 copies/ ml.